SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SARS and Avian Flu
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Condor who wrote (816)5/13/2003 3:40:41 PM
From: Biomaven  Read Replies (2) of 4232
 
<PFE>

I follow Pfizer (from a distance, at least).

A cold treatment trial is a very tough hurdle indeed - by the time you start treating the patient is practically already getting better and given it takes a few days for the drug effect to kick in it's hard to prove efficacy. Add to that a demand for absolute safety, and you have a tough hurdle to overcome. VPHM's pleconaril worked about as well as you could expect a cold drug to work, but still got turned down at the FDA. (It had some other problems, though).

In general, PFE is so big that a SARS drug would have little or no effect on its earnings (unless there was a major epidemic in a first-world country). PFE is probably the strongest of the big pharma in terms of pipeline and resources - however it isn't clear that that isn't already in the stock.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News